Predicting the future of anti-tumor necrosis factor therapy 英文参考文献.docVIP

Available online /content/11/3/115 Editorial Predicting the future of anti-tumor necrosis factor therapy Cornelis L Verweij Division of Inflammatory Disease Profiling, Department of Pathology and Rheumatology, VU University Medical Center, P.O. Box 7057, 1007MB Amsterdam, The Netherlands Corresponding author: Cornelis L Verweij, c.verweij@vumc.nl Published: 22 June 2009 Arthritis Research Therapy 2009, 11:115 (doi:10.1186/ar2724) This article is online at /content/11/3/115 ? 2009 BioMed Central Ltd See related research by Hueber et al., /content/11/3/R76 Abstract studies, such as gene expression profiling studies, in onco- logy have been considerable and this may account for the success in this field. For example, trastuzumab (Herceptin), an anti-human epidermal growth factor receptor 2 (HER2) mAb, is approved along with a diagnostic assay to select breast cancer patients with a high likelihood to benefit from therapy. However, such approaches have lagged behind in the field of rheumatology. Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approxi- mately two thirds of patients, reflecting that there are ‘responders’ as well as ‘nonresponders’. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, there is a strong need to make predictions on success before the start of therapy. In the current issue of Arthritis Research Therapy, Hueber and colleagues become the first to present a multi- parameter serum protein biomarker set that has predictive value prior to the start of anti-TNF treatment. Ultimately, this finding may contribute to a personalized form of medicine, whereby a specific therapy will be applied that is best suited to an individual patient. It is to be expected tha